학술논문
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
Document Type
Article
Author
Lu, Shun ; Zhou, Jianying ; Jian, Hong; Wu, Lin; Cheng, Ying; Fan, Yun; Fang, Jian; Chen, Gongyan; Zhang, Zhihong; Lv, Dongqing; Jiang, Liyan; Wu, Rong; Jin, Xiangming; Zhang, Xiaodong; Zhang, Junhong; Xie, Conghua; Sun, Gengyun; Huang, Dongning; Cui, Jiuwei; Guo, Renhua; Han, Zhigang; Chen, Zhendong; Liang, Jin; Zhuang, Wu; Hu, Xingsheng; Zang, Aimin; Zhang, Yi; Cang, Shundong; Lan, Yuanbo; Chen, Xi; Liu, Laiyu; Li, Xingya; Chen, Jun; Ma, Rui; Guo, Yanzhen; Sun, Ping; Tian, Panwen; Pan, Yueyin; Liu, Zhe; Cao, Peiguo; Ding, Lieming; Wang, Yang; Yuan, Xiaobin; Wu, Pengxiang
Source
In The Lancet Respiratory Medicine October 2023 11(10):905-915
Subject
Language
ISSN
2213-2600